Xarelto Reversal Agent in Late Stage Trial

A drug developed to rapidly reverse the effect of new blood thinners during episodes of major bleeding has been effective in late stage trials according to an article on Reuters.com. The drug reportedly reversed the anticoagulant effect of the new blood thinners, including Xarelto, with no serious side effects being reported. This is an important development because currently there is no known antidote to blood thinners like Xarelto so serious bleeding events are difficult if not impossible to control. Portola Pharmaceuticals, the maker of the drug, was hopeful it would be able to file for approval with the FDA by the end of the year.

Read more